You just read:

Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)

News provided by

Synthetic Biologics, Inc.

Jan 05, 2017, 06:58 ET